BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 15355561)

  • 1. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
    Wang L; Quarles LD; Spurney RF
    J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
    Wang L; Liu S; Quarles LD; Spurney RF
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells.
    Tanaka S; Sakai A; Tanaka M; Otomo H; Okimoto N; Sakata T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1813-20. PubMed ID: 15476581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
    Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
    J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.
    Locklin RM; Khosla S; Turner RT; Riggs BL
    J Cell Biochem; 2003 May; 89(1):180-90. PubMed ID: 12682918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluid flow induces Rankl expression in primary murine calvarial osteoblasts.
    Mehrotra M; Saegusa M; Wadhwa S; Voznesensky O; Peterson D; Pilbeam C
    J Cell Biochem; 2006 Aug; 98(5):1271-83. PubMed ID: 16514640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors.
    Gallant MA; Samadfam R; Hackett JA; Antoniou J; Parent JL; de Brum-Fernandes AJ
    J Bone Miner Res; 2005 Apr; 20(4):672-81. PubMed ID: 15765187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
    Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
    Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
    Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
    J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
    Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T
    J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics.
    Dai JC; He P; Chen X; Greenfield EM
    Bone; 2006 Apr; 38(4):509-20. PubMed ID: 16316790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
    Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
    J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.